TY - JOUR
T1 - Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression
T2 - A Bayesian analysis
AU - Kishi, Taro
AU - Ikuta, Toshikazu
AU - Matsuda, Yuki
AU - Iwata, Nakao
N1 - Funding Information:
We thank Mr Shinji Yamamoto [Kyowa Pharmaceutical Industry Co., Ltd. (Osaka, Japan 〒530-0005)] and Mr Masanobu Tatsumi [Kyowa Pharmaceutical Industry Co., Ltd. (Osaka, Japan 〒530-0005)] for providing information for Murasaki's study.
Funding Information:
The authors have declared that there are no conflicts of interest in relation to the subject of this study. We have had the following interests within the past 3 years. Dr. Kishi has received speaker's honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Janssen, Otsuka, Meiji, MSD, Yoshitomi, and Tanabe‐Mitsubishi and has received a Health Labour Sciences Research Grant, Grant‐in‐Aid for Scientific Research (C) and a Fujita Health University School of Medicine research grant. Dr. Ikuta received speaker's honoraria from Eli Lilly, Daiichi Sankyo, and Dainippon Sumitomo and is a consultant for Dainippon Sumitomo. Dr. Matsuda has received speaker's honoraria from Dainippon Sumitomo, Eisai, Otsuka, Tanabe‐Mitsubishi, and Pfizer and has received a grant‐in‐aid for Young Scientists (B). Dr. Iwata has received speaker's honoraria from Astellas, Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Yoshitomi, Otsuka, Meiji, Shionogi, Novartis, and Pfizer and has had research grants from Daiichi Sankyo, Dainippon Sumitomo, Meiji, and Otsuka.
Publisher Copyright:
© 2019 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of NeuropsychoPharmacology.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Objective: It is unknown whether there are differences in efficacy and safety between quetiapine extended-release, 300 mg/d (QUEXR300), and olanzapine, 5-20 mg/d (OLA), for Japanese patients with bipolar depression. Methods: We conducted a Bayesian analysis of data from phase 3 studies in Japan of QUEXR300 and OLA. Outcomes were remission rate (primary), response rate, improvement on the Montgomery-Åsberg Depression Rating Scale and 17-item Hamilton Depression Rating Scale scores, discontinuation rate, and incidence of individual adverse events. We calculated the standardized mean difference (SMD) and the risk ratio (RR) and 95% credible interval (95% CrI) for continuous and dichotomous data, respectively. Results: There were no significant differences between QUEXR300 and OLA for any of the efficacy outcomes. QUEXR300 was associated with a higher incidence of somnolence than OLA (RR = 5.517; 95% CrI = 1.563, 19.787), while OLA was associated with greater increase body weight (SMD = −0.488; 95% CrI = −0.881, −0.089) and blood prolactin levels (SMD = −0.642; 95% CrI = −1.073, −0.213) than QUEXR300, and a greater decrease in high-density lipoprotein cholesterol levels (SMD = −0.408; 95% CrI = −0.785, −0.030) than QUEXR300. Conclusion: Although the two drugs’ efficacy did not differ, OLA increased the risk of metabolic syndrome and QUEXR300 the risk of somnolence. A large scale, long-term, head-to-head comparison study of QUEXR300 vs OLA for Japanese patients with bipolar depression is needed to confirm the results of the current study.
AB - Objective: It is unknown whether there are differences in efficacy and safety between quetiapine extended-release, 300 mg/d (QUEXR300), and olanzapine, 5-20 mg/d (OLA), for Japanese patients with bipolar depression. Methods: We conducted a Bayesian analysis of data from phase 3 studies in Japan of QUEXR300 and OLA. Outcomes were remission rate (primary), response rate, improvement on the Montgomery-Åsberg Depression Rating Scale and 17-item Hamilton Depression Rating Scale scores, discontinuation rate, and incidence of individual adverse events. We calculated the standardized mean difference (SMD) and the risk ratio (RR) and 95% credible interval (95% CrI) for continuous and dichotomous data, respectively. Results: There were no significant differences between QUEXR300 and OLA for any of the efficacy outcomes. QUEXR300 was associated with a higher incidence of somnolence than OLA (RR = 5.517; 95% CrI = 1.563, 19.787), while OLA was associated with greater increase body weight (SMD = −0.488; 95% CrI = −0.881, −0.089) and blood prolactin levels (SMD = −0.642; 95% CrI = −1.073, −0.213) than QUEXR300, and a greater decrease in high-density lipoprotein cholesterol levels (SMD = −0.408; 95% CrI = −0.785, −0.030) than QUEXR300. Conclusion: Although the two drugs’ efficacy did not differ, OLA increased the risk of metabolic syndrome and QUEXR300 the risk of somnolence. A large scale, long-term, head-to-head comparison study of QUEXR300 vs OLA for Japanese patients with bipolar depression is needed to confirm the results of the current study.
UR - http://www.scopus.com/inward/record.url?scp=85071784839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071784839&partnerID=8YFLogxK
U2 - 10.1002/npr2.12070
DO - 10.1002/npr2.12070
M3 - Article
C2 - 31283865
AN - SCOPUS:85071784839
SN - 1340-2544
VL - 39
SP - 256
EP - 259
JO - Neuropsychopharmacology reports
JF - Neuropsychopharmacology reports
IS - 3
ER -